Medicinal composition containing caffeic acid ester and scutellarin, preparation method and application thereof

A technology of breviscapine and caffeic acid ester, applied in the field of medicinal preparations, can solve the problems of unstable preparations, excessive related substances, imperfect processes, etc., and achieve the effect of accurately removing impurities

Active Publication Date: 2015-05-06
YUNNAN BIOVALLEY PHARMA CO LTD
View PDF10 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there are already small-capacity injections of this type in production in my country, and there are very few manufacturers, mainly due to the imperfection of raw materials and preparation processes. For example, the preparations are unstable, related substances exceed the standard, and do not meet the relevant requirements for injection preparations, etc. series of questions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing caffeic acid ester and scutellarin, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] A medicinal composition containing caffeic acid ester and scutellarin, which is in the form of aqueous injection.

[0148] The weight ratio of caffeic acid ester and scutellarin contained in the composition is 1.2:1~19:1 (1.2:1~5.5:1);

[0149] Taking 10ml of injection as the unit of measurement, the dry matter content is 115-145 mg, the dry matter content of total caffeic acid esters and scutellarin is 8.2-20.0 mg (average value 12.5 mg); dicaffeoylquinic acid 7.2- 14.0mg (average value 10.6mg); wherein, the content of 3,4-O-dicaffeoylquinic acid in the dicaffeoylquinic acid is 1.4-2.3mg (average value 1.873mg), 3,5-O - dicaffeoylquinic acid 0.8-1.4mg (average value 1.063mg), 4,5-O-dicaffeoylquinic acid 1.5-2.6mg (average value 2.079mg), phenanthridine 1-2.6mg (average value Value 1.828mg), scutellarin 2.2-5.1mg (average value 3.619mg).

[0150] The caffeic acid ester and scutellarin are prepared by the following steps:

[0151] Take 800 g of Erigeron lanceolata, ad...

Embodiment 2

[0154] A medicinal composition containing caffeic acid ester and scutellarin, which is an injection.

[0155] The weight ratio of caffeic acid ester and scutellarin contained in the composition is 5.5:1;

[0156] Taking 10ml of injection as the unit of measurement, the dry matter content is 115-145 mg, the dry matter content of total caffeic acid esters and scutellarin is 8.2-20.0 mg (average value 12.5 mg); dicaffeoylquinic acid 7.2- 14.0mg (average value 10.6mg); Wherein, the content of 3,4-O-dicaffeoylquinic acid in the dicaffeoylquinic acid is 1.4-2.3mg (average value 1.873mg), 3,5-O Two-caffeoylquinic acid 0.8-1.4mg (average value 1.063mg), 4,5-O-dicaffeoylquinic acid 1.5-2.6mg (average value 2.079mg), 1-2.6mg (average value) Value 1.828mg), scutellarin 2.2-5.1mg (average value 3.619mg).

[0157] The caffeic acid ester and scutellarin are prepared by the following steps:

[0158] Take 800 g of Erigeron lanceolata, add water to decoct at least twice, combine the decocti...

Embodiment 3

[0160] A medicinal composition containing caffeic acid ester and scutellarin, which is an injection.

[0161] The weight ratio of caffeic acid ester and scutellarin contained in the composition is 1.2:1;

[0162] Taking 10ml of injection as the unit of measurement, the dry matter content is 115-145 mg, the dry matter content of total caffeic acid esters and scutellarin is 8.2-20.0 mg (average value 12.5 mg); dicaffeoylquinic acid 7.2- 14.0mg (average value 10.6mg); wherein, the content of 3,4-O-dicaffeoylquinic acid in the dicaffeoylquinic acid is 1.4-2.3mg (average value 1.873mg), 3,5-O - dicaffeoylquinic acid 0.8-1.4mg (average value 1.063mg), 4,5-O-dicaffeoylquinic acid 1.5-2.6mg (average value 2.079mg), phenanthridine 1-2.6mg (average value Value 1.828mg), scutellarin 2.2-5.1mg (average value 3.619mg).

[0163] The caffeic acid ester and scutellarin are prepared by the following steps:

[0164] Take 800 g of Erigeron lanceolata, add water to decoct at least twice, combi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicinal composition containing caffeic acid ester and scutellarin. The composition is a composition for injection, and comprises, by weight, 45-95% of caffeic acid ester and 5-25% of scutellarin. The invention also provides application of the composition in preparation of drugs for treating cardiovascular and cerebrovascular diseases.

Description

technical field [0001] The invention relates to pharmaceutical preparations in the field of medicine, in particular to a formula containing an injection composition prepared by a special process, a preparation process and application. Background technique [0002] Ischemic cardiovascular and cerebrovascular diseases such as stroke and coronary heart disease are the main causes of human death, and the fatality rate of acute attacks is extremely high. abnormality, reduce the quality of life, and bring heavy physical and mental and economic burdens to patients and their families. According to statistics, there are about 40 million patients in my country. With the aging of the population, the number of patients is still growing rapidly, and the number of new patients every year is as high as 4.5 million. The development of such preventive and therapeutic drugs is a hot spot in the world's new drug research. Cardiocerebral ischemia affects energy metabolism, secondary to variou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/28A61K9/08A61P9/00A61P9/10A61K31/7048
Inventor 杜江林炎海林艳和
Owner YUNNAN BIOVALLEY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap